Aktham Aburub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aktham Aburub has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
David C. Sperry
Lilly Research Labs, Eli Lilly & Company, Indianapolis, Indiana 46285
2 shared publicationsDinesh Mishra
Eli Lilly and Company, Pharmaceutical Sciences R&D, Lilly Research Laboratories, Indianapolis, IN 46285, United States
2 shared publications- Brian W. Pack
Eli Lilly and Company
1 shared publication Cherokee Sue Hoaglund Hyzer
Small Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana 46285, United States
1 shared publicationDale Eric Wurster
1 shared publication- Dale Eric Wurster
The National Institute for Pharmaceutical Technology and Education, Minneapolis, USA
1 shared publication
Latest Publications
- 13 June 2025
- Published by Springer Nature in Pharmaceutical Research
- Vol. 42 (6) , 1021-1033
Controlling Gastric Delivery of a GIP/GLP1 Peptide in Monkeys by Mucoadhesive SNAC Tablets
Objective Gastric delivery has been utilized for oral delivery of peptides. However, target site of the delivery is uncontrollable due to the housekeeping wave. In addition, dilution and spreading of peptides and permeation enhancers in the stomach may limit the oral peptide bioavailability. In this study, we developed mucoadhesive tablets containing SNAC and a GIP/GLP1 dual agonist peptide (LY) to localize the peptide delivery and minimize the dilution effect in the stomach. Methods The mucoadhesive tablets were prepared as bilayer or trilayer tablets with sodium alginate on one or both sides of the formulation layer (LY/SNAC). Mucoadhesion tests were conducted using a rotating cylinder mounted with isolated rat and minipig gastric tissues, and in vivo in monkeys. Oral bioavailability of the peptide was determined in monkeys via oral administration of the mucoadhesive tablets. Results The mucoadhesive tablets dissolved > 80% within 15 min at pH 6.8. The trilayer SNAC tablets adhered to the isolated gastric tissues. Following oral administration to monkeys, 10/10 mucoadhesive tablets were retained in the monkey stomach 10–20 min post-dose compared to 1/3 SNAC control tablets. Oral bioavailability of LY peptide was of similar magnitude as that achieved with the SNAC control tablet. In vivo dissolution of the mucoadhesive tablets was slower than the control tablets leading to lower SNAC concentration at the tablet site in the monkey stomach. Conclusion These data suggest that the mucoadhesive tablets improved gastric retention but did not increase oral bioavailability of the LY peptide following gastric delivery in monkeys.
- 13 June 2025
- Published by Springer Nature in Pharmaceutical Research
- Vol. 42 (6) , 1021-1033
Controlling Gastric Delivery of a GIP/GLP1 Peptide in Monkeys by Mucoadhesive SNAC Tablets
Objective Gastric delivery has been utilized for oral delivery of peptides. However, target site of the delivery is uncontrollable due to the housekeeping wave. In addition, dilution and spreading of peptides and permeation enhancers in the stomach may limit the oral peptide bioavailability. In this study, we developed mucoadhesive tablets containing SNAC and a GIP/GLP1 dual agonist peptide (LY) to localize the peptide delivery and minimize the dilution effect in the stomach. Methods The mucoadhesive tablets were prepared as bilayer or trilayer tablets with sodium alginate on one or both sides of the formulation layer (LY/SNAC). Mucoadhesion tests were conducted using a rotating cylinder mounted with isolated rat and minipig gastric tissues, and in vivo in monkeys. Oral bioavailability of the peptide was determined in monkeys via oral administration of the mucoadhesive tablets. Results The mucoadhesive tablets dissolved > 80% within 15 min at pH 6.8. The trilayer SNAC tablets adhered to the isolated gastric tissues. Following oral administration to monkeys, 10/10 mucoadhesive tablets were retained in the monkey stomach 10–20 min post-dose compared to 1/3 SNAC control tablets. Oral bioavailability of LY peptide was of similar magnitude as that achieved with the SNAC control tablet. In vivo dissolution of the mucoadhesive tablets was slower than the control tablets leading to lower SNAC concentration at the tablet site in the monkey stomach. Conclusion These data suggest that the mucoadhesive tablets improved gastric retention but did not increase oral bioavailability of the LY peptide following gastric delivery in monkeys.
- 1 January 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (1) , 8-17
Relative Bioavailability Risk Assessment: A Systematic Approach to Assessing In Vivo Risk Associated With CM&C-Related Changes
- 1 January 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (1) , 8-17
Relative Bioavailability Risk Assessment: A Systematic Approach to Assessing In Vivo Risk Associated With CM&C-Related Changes
- 1 August 2017
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 142, 307-314
Development of an in vivo -relevant drug product performance method for an amorphous solid dispersion
- 1 August 2017
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 142, 307-314
Development of an in vivo -relevant drug product performance method for an amorphous solid dispersion
- 7 March 2016
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 18 (1) , 202-211
Identification and Prevention of Particulates in a Parenteral Solution of a Protein Kinase B Inhibitor
The aim of this work was to identify the root cause of particulates in a parenteral solution formulation of a protein kinase B inhibitor (AKT inhibitor) and to devise a formulation fix. While standard potency/purity analyses did not reveal degradation, it was determined that the mass of the particulates corresponds to that of a "dimer-like" degradation product. The dimer-like molecule manifested itself as particulates rather than impurities in standard HPLC analysis. Particulate formation was found to be pH dependent. Consequently, an optimum formulation pH at which the compound has adequate solubility and the rate of particulate formation is slow was identified.
- 7 March 2016
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 18 (1) , 202-211
Identification and Prevention of Particulates in a Parenteral Solution of a Protein Kinase B Inhibitor
The aim of this work was to identify the root cause of particulates in a parenteral solution formulation of a protein kinase B inhibitor (AKT inhibitor) and to devise a formulation fix. While standard potency/purity analyses did not reveal degradation, it was determined that the mass of the particulates corresponds to that of a "dimer-like" degradation product. The dimer-like molecule manifested itself as particulates rather than impurities in standard HPLC analysis. Particulate formation was found to be pH dependent. Consequently, an optimum formulation pH at which the compound has adequate solubility and the rate of particulate formation is slow was identified.
- 17 September 2015
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 12 (10) , 3685-3690
Leveraging BCS in Development: A Case Study
In this work, we discuss leveraging the Biopharmaceutics Classification System (BCS) in the development of edivoxetine HCl, a selective norepinephrine reuptake inhibitor. First, the biopharmaceutical and in vivo data are presented and discussed. Solubility studies indicate that edivoxetine HCl meets the BCS “highly soluble” criteria. To determine permeability classifications, in vitro intestinal Caco-2 epithelial cell model with and without cyclosporin A (CsA), a common P-glycoprotein (P-gp) inhibitor, were conducted. Pharmacokinetic (PK) data obtained across phase 1 and 2 clinical studies where single and multiple doses range from the lowest to the highest strength are presented. Neither the Caco-2 nor the in vivo data on their own were sufficient to conclusively classify edivoxetine as highly permeable. However, collectively the data were utilized to support high permeability and consequently BCS1 classification of edivoxetine HCl. BCS1 classification was leveraged throughout development to assess the risk associated with not conducting relative bioavailability (RBA) studies and avoiding bioequivalence (BE) studies. Examples are presented where formulation changes were made between phase I (drug in capsule/drug in bottle formulations) and phase II (tablet) trials in addition to phase III (tablet) and commercial (smaller tablet) without having to conduct any in vivo comparability studies. For the first change, BCS was leveraged to avoid conducting a RBA study even before obtaining official BCS classification. For the later change, official BCS1 classification was relied upon to avoid conducting a BE study.
- 17 September 2015
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 12 (10) , 3685-3690
Leveraging BCS in Development: A Case Study
In this work, we discuss leveraging the Biopharmaceutics Classification System (BCS) in the development of edivoxetine HCl, a selective norepinephrine reuptake inhibitor. First, the biopharmaceutical and in vivo data are presented and discussed. Solubility studies indicate that edivoxetine HCl meets the BCS “highly soluble” criteria. To determine permeability classifications, in vitro intestinal Caco-2 epithelial cell model with and without cyclosporin A (CsA), a common P-glycoprotein (P-gp) inhibitor, were conducted. Pharmacokinetic (PK) data obtained across phase 1 and 2 clinical studies where single and multiple doses range from the lowest to the highest strength are presented. Neither the Caco-2 nor the in vivo data on their own were sufficient to conclusively classify edivoxetine as highly permeable. However, collectively the data were utilized to support high permeability and consequently BCS1 classification of edivoxetine HCl. BCS1 classification was leveraged throughout development to assess the risk associated with not conducting relative bioavailability (RBA) studies and avoiding bioequivalence (BE) studies. Examples are presented where formulation changes were made between phase I (drug in capsule/drug in bottle formulations) and phase II (tablet) trials in addition to phase III (tablet) and commercial (smaller tablet) without having to conduct any in vivo comparability studies. For the first change, BCS was leveraged to avoid conducting a RBA study even before obtaining official BCS classification. For the later change, official BCS1 classification was relied upon to avoid conducting a BE study.
- 1 January 2008
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 347 (1-2) , 16-22
A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe
- 1 January 2008
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 347 (1-2) , 16-22
A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe
- 1 January 2007
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 12 (4) , 405-414
Use of Compaction Energetics for Understanding Particle Deformation Mechanism
A primary goal of the current work was to examine the potential use of compaction energetics as a tool to predict particle deformation mechanism. Three deformation models, namely, those developed by Heckel, Walker, and Gurnham, were first used to evaluate the deformation mechanisms of 11 commonly used excipients. To complement the information gained from the deformation models, the mechanical energy used in tablet formation was then examined. It has been found that the sum of the work in the compression and decompression phases (plastic work) is a relatively good indicator of a material's plasticity. Conclusions based on this indicator regarding deformation mechanism for the different diluents used were in good agreement with those obtained from the different deformation models studied.
- 1 January 2007
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 12 (4) , 405-414
Use of Compaction Energetics for Understanding Particle Deformation Mechanism
A primary goal of the current work was to examine the potential use of compaction energetics as a tool to predict particle deformation mechanism. Three deformation models, namely, those developed by Heckel, Walker, and Gurnham, were first used to evaluate the deformation mechanisms of 11 commonly used excipients. To complement the information gained from the deformation models, the mechanical energy used in tablet formation was then examined. It has been found that the sum of the work in the compression and decompression phases (plastic work) is a relatively good indicator of a material's plasticity. Conclusions based on this indicator regarding deformation mechanism for the different diluents used were in good agreement with those obtained from the different deformation models studied.
- 1 July 2006
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 95 (7) , 1540-1548
The Effects of Surface Lactone Hydrolysis and Temperature on the Specific and Nonspecific Interactions Between Phenobarbital and Activated Carbon Surfaces
- 1 July 2006
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 95 (7) , 1540-1548
The Effects of Surface Lactone Hydrolysis and Temperature on the Specific and Nonspecific Interactions Between Phenobarbital and Activated Carbon Surfaces
- 1 April 2006
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 296 (1) , 79-85
Phenobarbital interactions with derivatized activated carbon surfaces
- 1 April 2006
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 296 (1) , 79-85
Phenobarbital interactions with derivatized activated carbon surfaces